ATTO Company Profile and Key Details

Average 10-day trading volume of 201.85 thousand shares is below the 3-month average of 232.56 thousand, indicating normal recent market interest.

Attovia Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended September 02, 2026, missed forecasts by 679.68%.

Attovia Therapeutics, Inc. (NASDAQ:ATTO) closed at $22.53 USD, losing -$0.33 (-1.44%) from the previous close of $22.86. The stock is currently mid-range between its 52-week high and low $16.15 and $28.00. With a market capitalization of about $969.47 million, Attovia Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 444.97 thousand shares, volume is running light vs its 52-week average. Headquartered in San Carlos, CA, Attovia Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tao Fu, the company employs approximately 44 people and listed since August 05, 2026. A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform.

Attovia Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.40. This means the shares are trading above this model’s fair value.

Valuation shows Attovia Therapeutics, Inc. trading at a premium to the broader market with a P/E of -25.09. Our AI forecast model points to short-term strength (11.36% over two weeks), a medium-term fall (-35.6% over three months), and a longer-term gain (835.77% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Attovia Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.36%, with price expected at $25.09 by September 24, 2026, within a range of $23.31 to $26.72 3-Month Outlook: Projected fall of -35.6%, reaching $14.51 by December 08, 2026, with a range of $14.35 to $14.68. 1-Year Outlook: Projected gain of 835.77%, with price at $210.83 by September 10, 2027, within a range of $210.65 to $210.99.

Attovia Therapeutics, Inc. trades at a P/E ratio of -25.09, slightly below the S&P 500 average, with a price-to-sales ratio of 2230.87 and a price-to-book ratio of 9.44 trading at moderately above to book value. The P/FCF stands at -28.44, also below market averages.